Your browser doesn't support javascript.
loading
Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.
Park, James H; Hothi, Parvinder; Lopez Garcia de Lomana, Adrian; Pan, Min; Calder, Rachel; Turkarslan, Serdar; Wu, Wei-Ju; Lee, Hwahyung; Patel, Anoop P; Cobbs, Charles; Huang, Sui; Baliga, Nitin S.
Affiliation
  • Park JH; Institute for Systems Biology, Seattle, WA.
  • Hothi P; Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA.
  • Lopez Garcia de Lomana A; Center for Systems Biology, University of Iceland, Reykjavik, Iceland.
  • Pan M; Institute for Systems Biology, Seattle, WA.
  • Calder R; Institute for Systems Biology, Seattle, WA.
  • Turkarslan S; Institute for Systems Biology, Seattle, WA.
  • Wu WJ; Institute for Systems Biology, Seattle, WA.
  • Lee H; Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA.
  • Patel AP; Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC.
  • Cobbs C; Center for Advanced Genomic Technologies, Duke University, Durham, NC.
  • Huang S; Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA.
  • Baliga NS; Institute for Systems Biology, Seattle, WA.
bioRxiv ; 2024 Feb 07.
Article in En | MEDLINE | ID: mdl-38370784
ABSTRACT
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity and treatment-induced shifts in phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This rare tumorigenic cell subpopulation resists temozolomide, undergoes proneural-to-mesenchymal transition (PMT) to evade therapy, and drives recurrence. Through inference of transcriptional regulatory networks (TRNs) of patient-derived GSCs (PD-GSCs) at single-cell resolution, we demonstrate how the topology of transcription factor interaction networks drives distinct trajectories of cell state transitions in PD-GSCs resistant or susceptible to cytotoxic drug treatment. By experimentally testing predictions based on TRN simulations, we show that drug treatment drives surviving PD-GSCs along a trajectory of intermediate states, exposing vulnerability to potentiated killing by siRNA or a second drug targeting treatment-induced transcriptional programs governing non-genetic cell plasticity. Our findings demonstrate an approach to uncover TRN topology and use it to rationally predict combinatorial treatments that disrupts acquired resistance in GBM.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2024 Document type: Article Country of publication: